{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:20:51Z","timestamp":1791807651270,"version":"4.3.4"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background and Aims:<\/jats:title>\n            <jats:p>Obeticholic acid (OCA) is a farnesoid X receptor agonist used in primary biliary cholangitis (PBC) treatment. Recent studies have expanded OCA use for NASH treatment and results from phase 3 clinical trial have shown beneficial reduction of \u22651 stage of fibrosis with no NASH worsening. However, safety concerns still preside, thus we systematically examine the safety profile of OCA in chronic liver disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>A search was conducted in Medline and Embase databases for OCA randomized controlled trials in chronic liver disease. Binary events were pooled with Paule-Mandel random effects model and proportional events were examined in a generalized linear mixed model with Clopper-Pearson intervals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 8 studies and 1878 patients were analyzed. There was a 75% [risk ratio (RR): 1.75, 95% CI: 1.43\u20132.15, <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.01] increased pruritis risk. OCA increased constipation incidence (RR: 1.88, 95% CI: 1.45\u20132.43, <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.01), decreased diarrhea (RR: 0.62, 95% CI: 0.50\u20130.77, <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.01), and increased development of hyperlipidemia (RR: 2.69, 95% CI: 1.85\u20133.92, <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.01) relative to placebo. Sensitivity analysis in NASH-only studies found a dose-dependent effect with pruritis which increases to RR: 3.07 (95% CI: 1.74\u20135.41) at 25\u00a0mg. However, up to 9.98% (95% CI: 5.01%\u201318.89%) of NAFLD patients with placebo similarly experience pruritis events. Overall, 16.55% (95% CI: 6.47%\u201336.24%) of patients with NAFLD on OCA experienced pruritis. There was no significant increase in cardiovascular events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>OCA may represent the first pharmacological treatment approved for NASH. However, pruritis, constipation, diarrhea, and hyperlipidemia were major events with evident dose-dependent effect that affect tolerability in NASH. Future long-term studies for longitudinal safety events are required.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/hc9.0000000000000005","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T17:01:48Z","timestamp":1675962108000},"page":"e0005-e0005","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":33,"title":["Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals"],"prefix":"10.1097","volume":"7","author":[{"given":"Cheng Han","family":"Ng","sequence":"first","affiliation":[{"name":"MBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansel Shao Pin","family":"Tang","sequence":"additional","affiliation":[{"name":"MBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieling","family":"Xiao","sequence":"additional","affiliation":[{"name":"MBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen Yu","family":"Wong","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie Ning","family":"Yong","sequence":"additional","affiliation":[{"name":"MBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa E.","family":"Fu","sequence":"additional","affiliation":[{"name":"MBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca W.","family":"Zeng","sequence":"additional","affiliation":[{"name":"MBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlyn","family":"Tan","sequence":"additional","affiliation":[{"name":"MBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Hong Zhe","family":"Wong","sequence":"additional","affiliation":[{"name":"MBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Teng","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Chee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren Jun Hao","family":"Tan","sequence":"additional","affiliation":[{"name":"MBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai En","family":"Chan","sequence":"additional","affiliation":[{"name":"MBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Q.","family":"Huang","sequence":"additional","affiliation":[{"name":"MBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"},{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore"},{"name":"National University Centre for Organ Transplantation, National University Health System, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas W.S.","family":"Chew","sequence":"additional","affiliation":[{"name":"MBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"},{"name":"Department of Cardiology, National University Heart Centre, National University Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Nah","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad S.","family":"Siddqui","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[{"name":"Houston Research Institute, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Muthiah","sequence":"additional","affiliation":[{"name":"MBBS Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"},{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore"},{"name":"National University Centre for Organ Transplantation, National University Health System, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3]]},"reference":[{"key":"R1-20240826","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","article-title":"Farnesoid X receptor (FXR): Structures and ligands","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"R2-20240826","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6\u03b1-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J Med Chem"},{"key":"R3-20240826","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/jpet.117.246033","article-title":"Farnesoid X receptor agonists obeticholic acid and chenodeoxycholic acid increase bile acid efflux in sandwich-cultured human hepatocytes: functional evidence and mechanisms","volume":"365","author":"Guo","year":"2018","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"R4-20240826","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/jpet.105.084905","article-title":"A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis","volume":"314","author":"Fiorucci","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"R5-20240826","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"R6-20240826","doi-asserted-by":"crossref","first-page":"609135","DOI":"10.3389\/fendo.2020.609135","article-title":"Sodium-glucose co-transporter 2 inhibitors for non-alcoholic fatty liver disease in asian patients with type 2 diabetes: a meta-analysis","volume":"11","author":"Wong","year":"2021","journal-title":"Front Endocrinol."},{"key":"R7-20240826","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"key":"R8-20240826","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","article-title":"Primary sclerosing cholangitis","volume":"382","author":"Hirschfield","year":"2013","journal-title":"Lancet"},{"key":"R9-20240826","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1007\/s10620-017-4684-x","article-title":"Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes","volume":"62","author":"Cholankeril","year":"2017","journal-title":"Dig Dis Sci"},{"key":"R10-20240826","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cgh.2021.11.014","article-title":"Outcomes of Nonalcoholic Steatohepatitis following Liver Transplantation: An Updated Meta-Analysis and Systematic Review","volume":"21","author":"Yong","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R11-20240826","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fmed.2020.00015","article-title":"Bile acid receptor therapeutics effects on chronic liver diseases","volume":"7","author":"Meadows","year":"2020","journal-title":"Front Med"},{"key":"R12-20240826","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"R13-20240826","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/apt.16808","article-title":"Meta\u2010analysis: analysis of mechanistic pathways in the treatment of non\u2010alcoholic steatohepatitis. Evidence from a Bayesian network meta\u2010analysis","volume":"55","author":"Ng","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R14-20240826","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14521","article-title":"A clinical overview of non\u2010alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications -- what the non\u2010specialist needs to know","volume":"24","author":"Muthiah","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"R15-20240826","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/hep.32315","article-title":"Placebo effect on progression and regression in NASH: Evidence from a meta\u2010analysis","volume":"75","author":"Ng","year":"2022","journal-title":"Hepatology"},{"key":"R16-20240826","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"R17-20240826","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"R18-20240826","author":"Chew"},{"key":"R19-20240826","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"R20-20240826","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"R21-20240826","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R22-20240826","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"R23-20240826","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R24-20240826","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/sim.4040","article-title":"Random effects meta\u2010analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data","volume":"29","author":"Stijnen","year":"2010","journal-title":"Stat Med"},{"key":"R25-20240826","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1002\/sim.7665","article-title":"Multistep estimators of the between\u2010-study variance: The relationship with the Paule\u2010Mandel estimator","volume":"37","author":"van Aert","year":"2018","journal-title":"Stat Med"},{"key":"R26-20240826","doi-asserted-by":"crossref","first-page":"e58327","DOI":"10.1371\/journal.pone.0058327","article-title":"The Mantel-Haenszel procedure revisited: models and generalizations","volume":"8","author":"Fidler","year":"2013","journal-title":"PLoS ONE"},{"key":"R27-20240826","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jrsm.1244","article-title":"Paule\u2010Mandel estimators for network meta\u2010analysis with random inconsistency effects","volume":"8","author":"Jackson","year":"2017","journal-title":"Res Synth Methods"},{"key":"R28-20240826","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R29-20240826","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/1469-0691.12494","article-title":"The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses","volume":"20","author":"Melsen","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R31-20240826","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gtc.2019.09.007","article-title":"Burden of disease due to nonalcoholic fatty liver disease","volume":"49","author":"Muthiah","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"key":"R32-20240826","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/hep.28958","article-title":"Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost\u2010effectiveness analysis","volume":"65","author":"Klebanoff","year":"2017","journal-title":"Hepatology"},{"key":"R33-20240826","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/17474124.2020.1748498","article-title":"Obeticholic acid for the treatment of nonalcoholic steatohepatitis","volume":"14","author":"Shah","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R34-20240826","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MOG.0000000000000525","article-title":"Obeticholic acid in primary biliary cholangitis: where we stand","volume":"35","author":"Manne","year":"2019","journal-title":"Curr Opin Gastroenterol"},{"key":"R35-20240826","doi-asserted-by":"crossref","first-page":"351","DOI":"10.7861\/clinmedicine.15-4-351","article-title":"Drug treatment of pruritus in liver diseases","volume":"15","author":"Hegade","year":"2015","journal-title":"Clin Med (Lond)"},{"key":"R36-20240826","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"R37-20240826","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/hep4.1581","article-title":"Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: the impact on patient\u2010reported outcomes","volume":"4","author":"Younossi","year":"2020","journal-title":"Hepatol Commun."},{"key":"R38-20240826","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side effect patterns in a crossover trial of statin, placebo, and no treatment","volume":"78","author":"Howard","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R39-20240826","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/hep4.1518","article-title":"Real\u2010world effectiveness of obeticholic acid in patients with primary biliary cholangitis","volume":"4","author":"Roberts","year":"2020","journal-title":"Hepatol Commun.Hepatol Commun"},{"key":"R40-20240826","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/biomedicines10020451","article-title":"Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease","volume":"10","author":"Boehlig","year":"2022","journal-title":"Biomedicines"},{"key":"R41-20240826","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/apt.16181","article-title":"Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid","volume":"53","author":"Gomez","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R42-20240826","first-page":"14309","article-title":"Placebo Adverse Events in Non-Alcoholic Steatohepatitis Clinical Trials. A Pooled Analysis of 2,944 Participants","volume":"10","author":"Tay","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"R43-20240826","doi-asserted-by":"crossref","first-page":"e000256","DOI":"10.1136\/bmjgast-2018-000256","article-title":"Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel","volume":"6","author":"Pate","year":"2019","journal-title":"BMJ Open Gastroenterol"},{"key":"R44-20240826","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.cgh.2021.09.021","article-title":"A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease","volume":"20","author":"Toh","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R45-20240826","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2021.0406","article-title":"Nafld increases risk of carotid atherosclerosis and ischemic stroke. An updated meta-analysis with 135,602 individuals","author":"Tang","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"R46-20240826","doi-asserted-by":"crossref","first-page":"924","DOI":"10.4254\/wjh.v8.i22.924","article-title":"Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications","volume":"8","author":"Nemes","year":"2016","journal-title":"World J Hepatol"},{"key":"R47-20240826","doi-asserted-by":"crossref","first-page":"119","DOI":"10.14218\/JCTH.2017.00064","article-title":"Risk of cardiovascular events in patients with primary biliary cholangitis-systematic review","volume":"6","author":"Suraweera","year":"2018","journal-title":"J Clin Transl Hepato"},{"key":"R48-20240826","first-page":"1042","article-title":"A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia","volume":"10","author":"Xiao","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"R49-20240826","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HC9.0000000000000005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T15:07:53Z","timestamp":1724684873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HC9.0000000000000005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/hc9.0000000000000005","relation":{},"ISSN":["2471-254X"],"issn-type":[{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"2022-09-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}